Immunovant, Inc. IMVT NASDAQ

Immunovant, Inc. (IMVT) reported total assets of $1.05B and total liabilities of $66.26M for quarter ending 2025-12-31, resulting in total equity of $986.14M.

The company held $994.53M in cash and short-term investments. Total debt stood at $0.00, with net debt of $-994.53M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 15.74, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0, current ratio of 15.74 — balance sheet is strong
• MOAT (40/100) — Total assets $1.05B and equity $986.14M support the company's competitive scale
• VALUE (43/100) — Debt-to-Equity 0 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 46/100 with 2/7 criteria passed.